Clinical Research and Prospects of Novel Intravenous Thrombolytic Agents for Acute Ischemic Stroke within the Standard Time Window

doi:10.3969/j.issn.1673-5765.2026.01.002

Abstract

Abstract: Reperfusion therapy is the cornerstone intervention for improving the prognosis of patients with acute ischemic stroke. Over the past three decades, alteplase has maintained a dominant position in the field of intravenous thrombolysis. However, its clinical applications are confronted with numerous practical challenges, including global supply shortages, cumbersome clinical administration protocols, and a relatively elevated risk of hemorrhage, all of which limit the widespread implementation of this therapeutic approach. Novel intravenous thrombolytic agents, including tenecteplase, reteplase, and prourokinase, have shown promising thrombolytic potential in preliminary exploratory studies. Recent confirmatory clinical trials have further demonstrated that these new intravenous thrombolytic agents exhibit non-inferior efficacy and safety profiles compared to alteplase. This review systematically summarizes the molecular structures, pharmacological properties, and key clinical trial data of these novel thrombolytic agents, provides an in-depth analysis of the clinical application characteristics of different agents, and discusses the emerging opportunities and challenges facing intravenous thrombolysis in the context of multiple therapeutic options. It aims to enhance the accessibility and standardization of intravenous thrombolysis for acute ischemic stroke, optimize the quality of medical services, and facilitate the advancement of intravenous thrombolysis for acute ischemic stroke into a new phase.

Key words: Acute ischemic stroke; Intravenous thrombolysis; Reteplase; Tenecteplase; Prourokinase

摘要： 再灌注治疗是改善急性缺血性卒中患者预后的核心手段。近三十年来，阿替普酶在静脉溶栓治疗领域长期占据主导地位，但其临床应用仍面临全球药物供应短缺、操作流程烦琐及出血风险相对较高等现实挑战，这制约了其临床应用的普及性。替奈普酶、瑞替普酶及尿激酶原等新型静脉溶栓药物在前期探索性研究中已初步展现出良好的溶栓潜力；近期完成的多项确证性临床研究进一步证实，这些新型静脉溶栓药物在疗效与安全性方面均不劣于阿替普酶。本文系统梳理了上述新型静脉溶栓药物的分子结构、药理学特性及重要临床研究数据，深入剖析了不同药物的临床应用特点，并探讨了在多药选择背景下静脉溶栓治疗面临的新机遇与挑战，旨在提升急性缺血性卒中静脉溶栓治疗的可及性与规范性，优化医疗服务质量，推动急性缺血性卒中静脉溶栓治疗迈入新阶段。

关键词: 急性缺血性卒中; 静脉溶栓; 瑞替普酶; 替奈普酶; 尿激酶原

CLC Number:

HE Dandan, XU Shuhong, LI Shuya. Clinical Research and Prospects of Novel Intravenous Thrombolytic Agents for Acute Ischemic Stroke within the Standard Time Window[J]. Chinese Journal of Stroke, 2026, 21(1): 24-29.

何丹丹, 许淑红, 李姝雅. 急性缺血性卒中标准时间窗内新型静脉溶栓药物临床研究及展望[J]. 中国卒中杂志, 2026, 21(1): 24-29.

References

[1] Institute for Health Metrics and Evaluation（IHME）. GBD results[EB/OL].（2025-10-12）[2026-01-08]. https://www.healthdata.org/data-tools-practices/interactive-visuals/gbd-results.
[2] WANG W Z，JIANG B，SUN H X，et al. Prevalence，incidence，and mortality of stroke in China：results from a nationwide population-based survey of 480 687 adults[J]. Circulation，2017，135（8）：759-771.
[3] WARDLAW J M，MURRAY V，BERGE E，et al. Thrombolysis for acute ischaemic stroke[J/OL]. Cochrane Database Syst Rev，2014（7）：CD000213[2025-12-08]. https://doi.org/10.1002/14651858.CD000213.pub3.
[4] 中华医学会神经病学分会，中华医学会神经病学分会脑血管病学组. 中国急性缺血性卒中诊治指南2023[J]. 中华神经科杂志，2024，57（6）：523-559.
Chinese Society of Neurology，Chinese Stroke Society. Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2023[J]. Chin J Neurol，2024，57（6）：523-559.
[5] IST-3 Collaborative Group，SANDERCOCK P，WARDLAW J M，et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke（the third international stroke trial [IST-3]）：a randomised controlled trial[J]. Lancet，2012，379（9834）：2352-2363.
[6] LLEVADOT J，GIUGLIANO R P，ANTMAN E M. Bolus fibrinolytic therapy in acute myocardial infarction[J]. JAMA，2001，286（4）：442-449.
[7] LOGALLO N，KVISTAD C E，THOMASSEN L. Therapeutic potential of tenecteplase in the management of acute ischemic stroke[J]. CNS Drugs，2015，29（10）：811-818.
[8] CAMPBELL B C V，MITCHELL P J，CHURILOV L，et al. Tenecteplase versus alteplase before thrombectomy for ischemic stroke[J]. N Engl J Med，2018，378（17）：1573-1582.
[9] CAMPBELL B C V，MITCHELL P J，CHURILOV L，et al. Effect of intravenous tenecteplase dose on cerebral reperfusion before thrombectomy in patients with large vessel occlusion ischemic stroke：the EXTEND-IA TNK Part 2 randomized clinical trial[J]. JAMA，2020，323（13）：1257-1265.
[10] LI S Y，PAN Y S，WANG Z R，et al. Safety and efficacy of tenecteplase versus alteplase in patients with acute ischaemic stroke（TRACE）：a multicentre，randomised，open label，blinded-endpoint（PROBE）controlled phase Ⅱstudy[J]. Stroke Vasc Neurol，2022，7（1）：47-53.
[11] WANG Y J，LI S Y，PAN Y S，et al. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events（TRACE-2）：a phase 3，multicentre，open-label，randomised controlled，non-inferiority trial[J]. Lancet，2023，401（10377）：645-654.
[12] MENON B K，SINGH N，SYLAJA P N. Tenecteplase use in patients with acute ischaemic stroke[J]. Lancet，2023，401（10377）：618-619.
[13] National clinical guideline for stroke for the UK and Ireland[EB/OL].（2023-05-04）[2025-12-08]. https://www.strokeguideline.org.
[14] MENG X，LI S Y，DAI H G，et al. Tenecteplase vs. alteplase for patients with acute ischemic stroke：the ORIGINAL randomized clinical trial[J]. JAMA，2024，332（17）：1437-1445.
[15] MENON B K，BUCK B H，SINGH N，et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada（AcT）：a pragmatic，multicentre，open-label，registry-linked，randomised，controlled，non-inferiority trial[J]. Lancet，2022，400（10347）：161-169.
[16] MUIR K W，FORD G A，FORD I，et al. Tenecteplase versus alteplase for acute stroke within 4.5 h of onset（ATTEST-2）：a randomised，parallel group，open-label trial[J]. Lancet Neurol，2024，23（11）：1087-1096.
[17] HAJJAR K A，REYNOLDS C M. Alpha-fucose-mediated binding and degradation of tissue-type plasminogen activator by HepG2 cells[J]. J Clin Invest，1994，93（2）：703-710.
[18] LARSEN G R，HENSON K，BLUE Y. Variants of human tissue-type plasminogen activator. Fibrin binding，fibrinolytic，and fibrinogenolytic characterization of genetic variants lacking the fibronectin finger-like and/or the epidermal growth factor domains[J]. J Biol Chem，1988，263（2）：1023-1029.
[19] NOBLE S，MCTAVISH D. Reteplase. A review of its pharmacological properties and clinical efficacy in the management of acute myocardial infarction[J]. Drugs，1996，52（4）：589-605.
[20] JINATONGTHAI P，KONGWATCHARAPONG J，FOO C Y，et al. Comparative efficacy and safety of reperfusion therapy with fibrinolytic agents in patients with ST-segment elevation myocardial infarction：a systematic review and network meta-analysis[J]. Lancet，2017，390（10096）：747-759.
[21] LI S Y，WANG X C，JIN A M，et al. Safety and efficacy of reteplase versus alteplase for acute ischemic stroke：a phase 2 randomized controlled trial[J]. Stroke，2024，55（2）：366-375.
[22] LI S Y，GU H Q，LI H，et al. Reteplase versus alteplase for acute ischemic stroke[J]. N Engl J Med，2024，390（24）：2264-2273.
[23] SHARMA M，SRIVASTVA A. In ischemic stroke treated within 4.5 h，reteplase vs. alteplase increased excellent functional outcome at 90 d[J/OL]. Ann Intern Med，2024，177（10）：JC115[2025-12-08]. https://doi.org/10.7326/ANNALS-24-02228-JC.
[24] HAO C H，DING W X，SUN Q，et al. Effect of human recombinant prourokinase（rhpro-UK）on thromboembolic stroke in rats[J/OL]. Eur J Pharmacol，2018，818：429-434[2025-12-08]. https://doi.org/10.1016/j.ejphar.2017.11.026.
[25] HAO C H，DING W X，XU X W，et al. Effect of recombinant human prourokinase on thrombolysis in a rabbit model of thromboembolic stroke[J]. Biomed Rep，2018，8（1）：77-84.
[26] DEL ZOPPO G J，HIGASHIDA R T，FURLAN A J，et al. PROACT：a phase Ⅱ randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke[J]. Stroke，1998，29（1）：4-11.
[27] SONG H Q，WANG Y，MA Q F，et al. Efficacy and safety of recombinant human prourokinase in acute ischemic stroke：a phase Ⅱa randomized clinical trial[J]. Transl Stroke Res，2022，13（6）：995-1004.
[28] SONG H Q，WANG Y，MA Q F，et al. Efficacy and safety of recombinant human prourokinase in the treatment of acute ischemic stroke within 4.5 hours of stroke onset：a phase 3 randomized clinical trial[J/OL]. JAMA Netw Open，2023，6（7）：e2325415[2025-12-08]. https://doi.org/10.1001/jamanetworkopen.2023.25415.
[29] LI S Y，GU H Q，FENG B Y，et al. Safety and efficacy of intravenous recombinant human prourokinase for acute ischaemic stroke within 4.5 h after stroke onset（PROST-2）：a phase 3，open-label，non-inferiority，randomised controlled trial[J]. Lancet Neurol，2025，24（1）：33-41.
[30] TURC G，NGUYEN T N. Reconsidering prourokinase for acute ischaemic stroke[J]. Lancet Neurol，2025，24（1）：2-3.
[31] 中国卒中学会，《中国卒中学会急性缺血性卒中再灌注治疗指南2024》编写组. 中国卒中学会急性缺血性卒中再灌注治疗指南2024[J]. 中国卒中杂志，2024，19（12）：1460-1478.
Chinese Stroke Association，Writing Group of Chinese Stroke Association Guidelines on Reperfusion Therapy for Acute Ischemic Stroke. Chinese Stroke Association guidelines on reperfusion therapy for acute ischemic stroke 2024[J]. Chin J Stroke，2024，19（12）：1460-1478.
[32] YUAN J，LU Z K，XIONG X M，et al. Age and geographic disparities in acute ischaemic stroke prehospital delays in China：a cross-sectional study using national stroke registry data[J/OL]. Lancet Reg Health West Pac，2023，33：100693[2025-12-08]. https://doi.org/10.1016/j.lanwpc.2023.100693.